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A B S T R A C T
Background: Recurrence after catheter ablation of persistent atrial ﬁbrillation (AF) remains an unsolved
issue. This study aimed to explore the association between the left atrial appendage peak ﬂow velocity
(LAAV) and AF recurrence after ablation in persistent AF patients.
Methods: Fifty-three consecutive patients who underwent an initial catheter ablation of persistent AF
were enrolled [age, 65  10 years; male, 42 (79%)]. The LAAV was obtained by transesophageal
echocardiography before ablation. All the patients underwent pulmonary vein isolation and were followed
up for 12 months. The LAAV and other clinical factors (AF duration, CHA2DS2VASc score, left atrial diameter,
left atrial volume, and left ventricular ejection fraction) were tested using a Cox proportional hazards
regression analysis as predictors of AF recurrence during the 1-year follow-up.
Results: AF recurrence occurred in 16 (30%) patients. The patients with AF recurrences had lower LAAVs
(23.3  7.2 cm/s vs. 33.3  15.1 cm/s, p = 0.002) than those without AF recurrence. In the multivariable
analysis, a low LAAV independently predicted AF recurrence (hazard ratio, 3.04; 95% conﬁdence interval,
1.05–8.79; p = 0.040). A Kaplan–Meier analysis also demonstrated a lower survival rate free from AF
recurrence in the low LAAV group than in the high LAAV group (p = 0.030).
Conclusion: A low LAAV was associated with AF recurrence after the initial catheter ablation of
persistent AF.
 2015 Published by Elsevier Ltd on behalf of Japanese College of Cardiology.
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Atrial ﬁbrillation (AF) is one of the most common arrhythmias
dealt with in the clinical setting. The efﬁcacy of catheter ablation of
paroxysmal AF has been established; however, that of persistent
AF, especially long-standing persistent AF, is not sufﬁcient and has* Corresponding author at: Kansai Rosai Hospital Cardiovascular Center, 3-1-69
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0914-5087/ 2015 Published by Elsevier Ltd on behalf of Japanese College of Cardioloa higher recurrence rate than that of paroxysmal AF [1,2]. There-
fore, the estimation of the probability of an AF recurrence before
ablation is important for considering the procedural indications
and management of patients with persistent AF.
Some variables have been reported to have a potential role in
predicting outcomes after ablation; for example, the AF duration,
CHADS2/CHA2DS2VASc score, left atrial (LA) diameter and volume,
and echocardiographic parameters [3–5]. However, there is no
sufﬁciently reliable parameter to predict AF recurrence after
ablation. On the other hand, previous studies reported that a high
recurrence rate correlated with a low LA function [3–5]. The left
atrial appendage peak ﬂow velocity (LAAV) during AF wasgy.
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we hypothesized that a low LAAV would predict AF recurrence. The
purpose of this study was to explore the association between the
LAAV and AF recurrence after ablation in patients with persistent
AF.
Methods
Study population
From January 2011 to April 2012, we enrolled consecutive
patients with symptomatic persistent AF who were scheduled for
an initial catheter ablation. Persistent AF was deﬁned as AF that
had been present for 1 week or more. Patients who did not undergo
transesophageal echocardiography prior to ablation were exclud-
ed. Other exclusion criteria were as follows: an age <20 years,
pregnancy, prior cardiac surgery, and severe mitral valve disease.
Written informed consent for the ablation and participation in the
study was obtained from all patients.
Transesophageal echocardiography
Transesophageal echocardiography was performed within 24 h
prior to the ablation (Artida or Aplio, Toshiba Medical Systems,
Tochigi, Japan). LA appendage images were obtained both in the
basal short-axis view with a transverse scan and in the left ventricle-
LA 2 chamber view with a vertical scan. We evaluated the presence
or absence of thrombi, a smoke-like echo, and the LAAV. The LAAV
was obtained by pulsed-wave Doppler interrogation at the entry of
the LA appendage (Fig. 1). The LAAV was measured as the average
value of 10 consecutive ﬁbrillatory emptying waves [7].Fig. 1. Examples of measuring the left atrial appendage velocity (LAAV). The LAAV was obt
at 608 (38 cm/s).Electrophysiological study and catheter ablation procedure
All the patients received effective anticoagulation therapy
(vitamin K antagonists, target international normalized ratio of
2.0–3.0) for more than 1 month before the ablation. This therapy
was not interrupted before or after the procedure. The electrophys-
iological study and ablation were performed under intravenous
sedation using dexmedetomidine with an initial injection of 6 mg/
kg/h for 10 min followed by 0.2–0.7 mg/kg/h during the procedure.
The following catheters were introduced via the femoral vein and
internal jugular vein: a 20-pole steerable catheter (Inquiry; St. Jude
Medical, St. Paul, MN, USA) was positioned within the coronary
sinus; 2 circumferential mapping catheters (Lasso; Biosense
Webster, Diamond Bar, CA, USA and Optima; St. Jude Medical)
were introduced after transseptal access; and a 3.5-mm externally
irrigated-tip ablation catheter (Thermocool; Biosense Webster)
was used for mapping and ablation. After transseptal access, a
single bolus of heparin (5000 IU) was administered. The infusion
was adjusted to maintain an activated coagulation time (ACT) of
300 s or more by checking the ACT every 30 min.
The ablation procedure was as follows. First, all the patients
underwent circumferential pulmonary vein isolation using dou-
ble-lasso technique during AF. The endpoint of the pulmonary vein
isolation was the electrical isolation of all four pulmonary veins
from the left atrium. If AF continued after the pulmonary vein
isolation, biphasic direct current shocks with an energy of 100–
270 J were administered to restore sinus rhythm. Then, a LA roof
line ablation was added at the discretion of the operator. A roof line
was drawn between the right and left superior pulmonary veins
and the block line was conﬁrmed. If AF triggered by atrial
premature beats originating from non-pulmonary vein foci
occurred, we tried to eliminate the atrial ectopic foci. Finally, aained by pulsed-wave Doppler interrogation at the entry of the left atrial appendage
Table 1
Patient characteristics.
No recurrence
(n = 37)
Recurrence
(n = 16)
p-Value
Clinical characteristics
Age, years 64  11 67  7 0.33
Male, n (%) 31 (84) 11 (69) 0.28
Body mass index 24.1  3.5 22.7  3.7 0.22
Heart rate, beat per minute 98  25 96  25 0.82
Systolic blood pressure, mmHg 131  13 124  16 0.14
Diastolic blood pressure, mmHg 77  11 72  11 0.11
Duration of atrial ﬁbrillation, month 20  26 65  81 0.04
Heart failure, n (%) 9 (24) 6 (38) 0.34
Hypertension, n (%) 12 (32) 10 (63) 0.70
Diabetes mellitus, n (%) 3 (8) 5 (31) 0.09
Stroke, n (%) 9 (24) 2 (13) 0.74
Vascular disease, n (%) 4 (11) 2 (13) 0.86
CHADS2 score 1.5  0.9 2.0  1.3 0.11
CHA2DS2VASc score 2.2  1.3 2.8  1.3 0.15
Antiarrhythmic drugs
Class I 7 (19) 5 (31) 0.33
Class III 1 (3) 3 (19) 0.04
Beta-blocker 13 (35) 9 (56) 0.15
Echocardiographic parameters
Left ventricular ejection fraction, % 61  11 63  10 0.04
Left atrial diameter, mm 44  5 44  5 0.59
Left atrial volume index, ml/m2 53  14 68  17 0.01
Left atrial smoke-like echo 17 (46) 10 (63) 0.26
Ablation procedures
Additional roof ablation, n (%) 21 (57) 13 (81) 0.53
Antiarrhythmic drugs after ablation
Class I 6 (16) 3 (19) 0.82
Class III 7 (19) 5 (31) 0.33
Beta-blocker 13 (35) 10 (63) 0.07
Systolic blood pressure after ablation 131  13 123  19 0.07
Diastolic blood pressure after ablation 77  11 72  9 0.10
Fig. 2. Comparison of the LAAV between patients with and without AF recurrence.
The LAAV was signiﬁcantly lower in the patients with than in those without AF
recurrence. LAAV, left atrial appendage ﬂow velocity; AF, atrial ﬁbrillation.
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bidirectional conduction block was conﬁrmed.
Follow-up and AF recurrence assessment
All the patients were followed up for 12 months after ablation.
AF recurrence was assessed before discharge and at the 3rd, 6th,
and 12th months by a clinical interview, routine 12-lead
electrocardiogram (ECG), and 24-h Holter monitoring. In addition,
patients who developed symptoms suggestive of AF were
instructed to visit our hospital for an immediate ECG recording
or performed ambulatory ECG-event recording for the assessment.
Vitamin K antagonists were prescribed for a minimum of 6 months
and potentially discontinued in the case of a low thromboembolic
score (CHADS2 score 0 or 1). Antiarrhythmic drugs were continued
for at least 3 months in patients who were receiving antiarrhyth-
mic drugs before the procedure, and were interrupted in the case of
no AF recurrence at 3 months. AF recurrence was deﬁned when
patients developed the following arrhythmias: (1) AF or any other
atrial tachyarrhythmia lasting for >30 s by Holter monitoring, or
(2) those observed by a routine or symptom-triggered 12-lead ECG.
Statistical analysis
Categorical values are expressed as absolute and relative
frequencies. Continuous values are expressed as means  standard
deviation. Tests for signiﬁcance were conducted using the unpaired
t-test or nonparametric test (Mann–Whitney U test) for continuous
variables and the chi-square test or Fisher’s exact test for categorical
variables. The duration of AF, CHADS2 score, CHA2DS2VASc score, left
ventricular ejection fraction, LA diameter, LA volume index, and LAAV
were considered in a Cox proportional hazards regression model to
identify parameters associated with AF recurrence following the
catheter ablation. Categorized variables with a p-value <0.20 in the
univariate analysis were then considered in a multivariate analysis to
identify any independent predictors of AF recurrence. The LA volume
index and LAAV were studied by using a receiver operating
characteristics (ROC) curve to determine the optimal cut-off values
for the prediction of AF recurrence. The best cut-off value was deﬁned
as the point combining the highest sensitivity and speciﬁcity. The
event-free survival rate was estimated by the Kaplan–Meier method
and comparisons between different groups were done by a log-rank
test. All statistical analyses were performed using SPSS software,
version 22 software (SPSS; Chicago, IL, USA).
Results
Patient characteristics
During the study period, 55 patients underwent ablation of
persistent AF, and 2 (4%) were excluded due to lack of transeso-
phageal echocardiography. Therefore, 53 patients were ﬁnally
included in this study. On-drug AF recurrence occurred in 16
(30%) patients during a 12-month follow-up. The comparisons of
baseline characteristics between the patients with and without AF
recurrence are shown in Table 1. There was no difference in the age,
sex, and body mass index between the groups. Patients with AF
recurrence had a longer AF duration and tended to have concomitant
diabetes mellitus more frequently. As for the echocardiographic
parameters, the patients with AF recurrence had a slightly higher left
ventricular ejection fraction, and larger LA volume index.
Circumferential pulmonary vein isolation and cavotricuspid
isthmus ablation were completed in all the patients. Of the
53 patients, in 39 (74%) a LA roof line ablation was added, and the
proportion of patients receiving this procedure was comparable
between those with and without an AF recurrence.LAAV and other clinical parameters
As depicted in Fig. 2, the LAAV was signiﬁcantly lower in the
patients with than without AF recurrences. A negative weak
correlation between the LAAV and LA volume index was observed
(r = 0.31, p = 0.04). On the other hand, the LAAV did not correlate
with the gender (male, 30.3  14.3 cm/s vs. female, 29.9  13.0 cm/
s, p = 0.93), age (r = 0.01, p = 0.79), body mass index (r = 0.09,
p = 0.54), AF duration (r = 0.09, p = 0.52), hypertension (with,
31.6  12.4 cm/s vs. without, 29.3  15.0 cm/s, p = 0.55), diabetes
Table 2
Univariate and multivariate analyses for the association with the recurrence of atrial ﬁbrillation.
Univariate analysis Multivariate analysis
Unadjusted hazard ratio
[95% conﬁdence interval]
Adjusted hazard ratio
[95% conﬁdence interval]
Female 2.56 [1.08,6.05] (p = 0.031) – –
Age 1.03 [0.85,1.12] (p = 0.73) – –
Heart failure 0.69 [0.30,1.57] (p = 0.38) – –
Hypertension 1.05 [0.47,2.37] (p = 0.90) – –
Age >75 years 1.16 [0.43,3.10] (p = 0.77) – –
Diabetes mellitus 2.15 [0.79,5.78] (p = 0.13) – –
Stroke 0.83 [0.19,3.52] (p = 0.80) – –
Vascular disease 0.05 [0.00,123] (p = 0.44) – –
Age >65 years 2.21 [0.95,5.19] (p = 0.07) – –
Ejection fraction 1.02 [0.97,1.07] (p = 0.48) – –
LA diameter 0.98 [0.92,1.04] (p = 0.47) – –
LAVI 60 ml/m2 2.38 [1.02,5.58] (p = 0.05) 1.51 [0.63,3.62] (p = 0.35)
LAAV 28 cm/s 3.38 [1.33,8.56] (p = 0.01) 3.24 [1.24,8.48] (p = 0.02)
Smoke-like echo 1.37 [0.61,3.05] (p = 0.45) – –
Duration 2 years 3.46 [1.47,8.15] (p = 0.01) 2.91 [1.22,6.97] (p = 0.02)
CHA2DS2VASc score 2 2.86 [1.07,7.70] (p = 0.04) 2.89 [1.04,8.02] (p = 0.04)
LA, left atrial; LAVI, left atrial volume index; LAAV, left atrial appendage ﬂow velocity.
Fig. 3. Kaplan–Meier of the time to AF recurrence. The study patients were divided
into two groups based on the best cut-off value of the LAAV for the prediction of an
AF recurrence. Patients with an LAAV of <28 cm/s had a lower survival rate free
from AF recurrence. LAAV, left atrial appendage ﬂow velocity; AF, atrial ﬁbrillation.
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p = 0.69), left ventricular ejection fraction (r = 0.15, p = 0.26), or LA
diameter (r = 0.22, p = 0.11). The correlation coefﬁcient of LAAV
measurements between two observers was 0.91 (p < 0.001). The
mean difference + SD was 0.5 + 3.5 cm/s.
Prediction of AF recurrence
To investigate the associations between the various clinical
parameters and AF recurrence, a Cox proportional hazards regres-
sion analysis was made as shown in Table 2. In the univariate
analysis, a low LAAV, long AF duration, high CHA2DS2VASc score, and
high LA volume index were related to an AF recurrence. In the
multivariable analysis, a low LAAV remained as having a signiﬁcant
association with AF recurrence.
An ROC curve analysis revealed that the best cut-off value of the
LAAV for the prediction of an AF recurrence was 28 cm/s with a
sensitivity of 62%, speciﬁcity of 69%, and predictive accuracy of
63%. When the study patients were divided into two groups by the
cut-off value of the LAAV, the Kaplan–Meier curves demonstrated
that patients with a low LAAV, rather than those without it, had a
higher AF recurrence rate (Fig. 3).
Discussion
We studied 53 patients undergoing an initial catheter ablation
of persistent AF and investigated the relationship between the
preprocedural LAAV and AF recurrence during a 1-year follow-up
after ablation. The main ﬁnding was that a low preprocedural LAAV
was independently associated with an AF recurrence. To the best of
our knowledge, this is the ﬁrst clinical study to evaluate the
efﬁcacy of the LAAV for the prediction of an AF recurrence in
patients with persistent AF.
There are some electrophysiological mechanisms of AF recur-
rence after ablation. A reconnection of the LA-pulmonary vein
conduction is one of the most common mechanisms. Verma et al.
reported that 95–100% of patients with AF recurrences had
resumption of conduction at the LA-pulmonary vein junction, and
81% of patients without AF recurrences had no pulmonary vein
reconnections [8]. In patients with severe LA remodeling it is
probably possible to have more frequent LA-pulmonary vein
reconnections because of the longer isolation line and more
difﬁcult catheter manipulation in the LA. In addition, patients with
advanced atrial remodeling would have a residual arrhythmogenicsubstrate after the pulmonary vein isolation, such as abnormal
automaticity or a conduction disturbance in the atrium. Although there
is no deﬁnite parameter of LA remodeling, the LAAV would reﬂect the
variety of the LA appendage function including its contractility,
stunning, and ﬁbrosis; therefore, the LAAV might represent the
comprehensive LA function and severity of the LA remodeling as
reported previously [9,10]. However, Agmon et al. mentioned LAAV
should not be used as surrogates of global LA function [9].
Some previous studies have reported a preprocedural high LAAV
as a predictor of sinus rhythm maintenance after external electrical
cardioversion and catheter ablation. Antonielli et al. showed that an
LAAV of >40 cm/s could independently predict sinus rhythm
persistence at 1 year after a successful electrical cardioversion in
a prospective multicenter study of 193 patients [11]. We thought
reduced LA function could be expressed in low LAAV, however, as far
as we know, there are no data describing the study on the association
between LAAV and histopathological change in LA.
Other clinical parameters, such as LA structural dilation (LA
dimension and volume) and the duration of AF, have also been
T. Kanda et al. / Journal of Cardiology 66 (2015) 377–381 381reported as predictors of AF recurrence after ablation. These
parameters similarly reﬂect the severity of the LA remodeling
similar to the LAAV; however, the results of this study
demonstrated that the LAAV was superior to those as a predictor
of AF recurrence. The LAAV mainly depends on the contraction of
the LA appendage and reﬂects a more comprehensive atrial
remodeling as mentioned above, and therefore, would be a more
reliable predictor of AF recurrence. This is similar to the
observation that the left ventricular ejection fraction is a strong
predictor of ventricular tachyarrhythmias among patients with left
ventricular dysfunction [12]. In addition, there may be other
reasons that would reduce the reliability of the other predictors of
AF. First, it is difﬁcult to precisely estimate LA structural dilation.
The LA dimension has been found to be inferior to the LA volume as
an indicator of LA remodeling [13]. However, the LA volume has
some difﬁculty in its measurement, because there is no landmark
which divides the LA and pulmonary vein. Furthermore, in most
clinical settings, an estimation of the AF duration is vague because
we often have to estimate it from patient interviews.
Clinical implications
This study demonstrated that the preprocedural LAAV pre-
dicted AF recurrences after ablation. This method may enable us to
distinguish patients with persistent AF who would have a
preferable outcome by catheter ablation from those who would
not, and could improve the clinical decision-making in these
patients. In addition, it is possibly suggested that patients with a
low LAAV may need further linear and/or electrogram-based
ablation procedures in order to reduce the AF recurrence.
Study limitations
There are several limitations to this study. First, the measure-
ment of the LAAV had some difﬁculties because it was dependent
on the Doppler angle and could change substantially from beat to
beat. Second, the ECG and periodic Holter monitoring may have led
to some degree of underestimation of the recurrence rates. In
addition, we recognized the development of AF immediately after
the ablation as an AF recurrence, which may have been a
temporary phenomenon due to the inﬂammation provoked by
the ablation. Therefore, the AF recurrence in this study may have
differed from a true AF recurrence. Third, we used the same
patients to determine the best cut-off value of the LAAV for the
prediction of AF recurrence and to evaluate the diagnostic
performance of the determined cut-off value, which was not
necessarily a fair method to test the diagnostic performance.
Lastly, our sample size was small and study design wasretrospective. A future study including a larger number of patients
is required to determine our conclusions.
Conclusions
A low LAAV was associated with an AF recurrence after the
initial catheter ablation of persistent AF. The LA appendage peak
ﬂow velocity was not correlated with the classical parameters
predicting AF recurrence such as the AF duration and LA diameter.
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